JP Morgan has upgraded the communications firm to “overweight” from “neutral” with an 80p target, arguing that its recent share performance is unwarranted. JP Morgan points to the firms’ “attractive returns” and “solid operations”.
UBS reiterates its “buy” rating on the biopharmaceutical firm, with a target price of 2,250p. The bad news that its drug Lialda could not treat diverticulitis has been overstated, UBS said, while upside opportunities remain.
Deutsche Bank has chipped its recommendation on the department store down to “hold” from “buy” with a target price of 85p. The bank expects a strong first half performance to be reported this month, yet prefers Next and ASOS in the clothes sector.